Developing radiocaine NAV imaging as a response monitoring biomarker for chronic pain
Ended Cooperative Agreement Awarded Last action
- Award ID
- UG3NS135173
- Recipient
-
Lutroo Imaging LLC UEI VN11L9CEJKG4
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $478,242
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- There are currently no biomarkers or tools capable of objectively measuring pain signals. Historically, pain in humans has been measured using subjective rating scales to determine its presence and severity. In animal models, pain is measured by semi-quantitative assays that rely on the observation of pain behaviors. Though useful, the inherently subjective nature of these measures has hampered both research and treatment efforts. The annual economic burden of chronic pain is estimated to exceed $800 billion in the USA alone, largely because inadequately managed pain requires disproportionately more healthcare resources. Similarly, clinical trials for pain therapies are the most expensive, and have the lowest success rate, of all neurological indications. Difficulty managing chronic pain has led to the opioid epidemic as many individuals turn to prescription painkillers as a means of relief, but often end up becoming addicted and resorting to more potent and dangerous opioids as their tolerance increases. Radiocaine is a novel positron emission tomography (pet) imaging agent that we are developing as a biomarker to address the issues in pain care and therapy development. Our recently published findings in a rodent model of neuropathic pain demonstrate the ability to localize the pain generator rapidly and accurately and objectively measure its signal intensity. Our ultimate goals are: 1) to change the evaluation of (experimental) pain therapies, and 2) the standard of care in pain assessment through molecular imaging. The use of pain imaging biomarker technology would allow for objective efficacy data (both pre-clinically and in clinical trials), and reduce costs by enabling smaller sample sizes due to more homogeneous populations, i.e. with a particular "pain signal," and more accurate measurement of analgesic effects. The proposed study will evaluate radiocaine in early-stage clinical trials. Successful results will set the stage for applied clinical trials that further develop this promising approach into a useful biomarker for transforming pain care.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$627,778 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $1,106,020 |
Quick answers
Who received award UG3NS135173?
UG3NS135173 was awarded to Lutroo Imaging LLC by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 21, 2023.
How much is award UG3NS135173 worth?
$478,242 has been obligated on UG3NS135173.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award